Available under a Creative Commons Attribution Non-Commercial Share Alike 4.0 International Licence
1.4 CHEMICAL SCIENCES, Medical engineering
We report the development of a microfluidic device for the rapid assay in whole blood of platelet-protein interactions indicative of the efficacy of antiplatelet drugs—e.g., aspirin and Plavix, two of the world’s most widely used drugs—in cardiovascular patients. Because platelet adhesion to surface-confined protein matrices is modulated by fluid shear rates at the blood/protein interface, and because such binding is a better indicator of platelet function than platelet self-aggregation, we designed, fabricated, and characterized the performance of a family of disposable, self-powered microfluidic chips with well-defined flow and interfacial shear rates suitable for small blood volumes (≤ 200 µL). We report a simple technique to fabricate single-use self-powered chips incorporating shear control, “SpearChips”. These parallel-plate flow devices integrate on-chip vacuum-driven blood flow, using a pre-degassed elastomer component to obviate active pumping, with microcontact-printed arrays of 6-µm-diameter fluorescently-labeled fibrinogen dots on a poly(cycloolefin) base plate as a means to quantitatively count platelet-protein binding events. The use of SpearChips to assess in whole blood samples the effects of GPIIb/IIIa and P2Y12 inhibitors—two important classes of “antiplatelet” drugs—is reported.
Jose B, McCluskey P, Gilmartin N, Somers M, Kenny D, Ricco AJ, Kent NJ, Basabe-Desmonts L. Self-Powered Microfluidic Device for Rapid Assay of Antiplatelet Drugs. Langmuir. 2016 Mar 22;32(11):2820-8. doi: 10.1021/acs.langmuir.5b03540. Epub 2016 Mar 8. PMID: 26910300.
Science Foundation Ireland